{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:57:28Z","timestamp":1774630648196,"version":"3.50.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Whether the diagnosis of non-alcoholic fatty liver disease or metabolic dysfunction-associated fatty disease has a different impact on liver transplant recipients with hepatocellular carcinoma is not yet clear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data from a two-center retrospective cohort study were collected to compare and investigate the differences between non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in clinicopathologic parameters and prognosis among liver transplant recipients with hepatocellular carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 268 liver transplant recipients with hepatocellular carcinoma were included. The prevalence among pre- and post-transplant metabolic dysfunction-associated fatty liver disease was 10.82% and 30.22%, while for non-alcoholic fatty liver disease, it was 7.09% and 26.87%, respectively. The clinicopathological parameters were similar between the two pre-transplant groups. In contrast, the post-transplant group with metabolic dysfunction-associated fatty liver disease exhibited a higher prevalence of diabetes mellitus and a greater body mass index. However, the other parameters were similar between the two post-transplant groups (p &amp;gt; 0.05). Factors such as the largest tumor size &amp;gt; 4\u00a0cm, microvascular invasion, lack of tumor capsule, post-transplant metabolic dysfunction-associated fatty liver disease, and decreased post-transplant lymphocyte percentage were related to an increased risk of recurrence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients undergone liver transplantation for hepatocellular carcinoma, the diagnosis of metabolic dysfunction-associated fatty disease is more strongly associated with metabolic abnormalities than the diagnosis of non-alcoholic fatty liver disease and is an independent predictor of hepatocellular carcinoma recurrence.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2024.1306091","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T04:12:30Z","timestamp":1713154350000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Ji-Qiao","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Zong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang-Yong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Yong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Dong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cgh.2012.10.001","article-title":"Association between nonalcoholic fatty\u00a0liver\u00a0disease and risk for hepatocellular cancer, based on systematic review","volume":"10","author":"White","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14521","article-title":"A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications-What the non-specialist needs to know","author":"Muthiah","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-013-9446-z","article-title":"Current histological classification of NAFLD: strength and limitations","author":"Bedossa","year":"2013","journal-title":"Hepatol Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14548","article-title":"Comparison of MAFLD and NAFLD diagnostic criteria in real world","volume":"40","author":"Lin","year":"2020","journal-title":"Liver Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05002.x","article-title":"Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary","volume":"22","author":"Farrell","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/clinem\/dgab641","article-title":"Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: A 4.6-year cohort study in China","volume":"107","author":"Liang","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.cgh.2021.11.038","article-title":"An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD","volume":"21","author":"Lim","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.779443","article-title":"The model for end-stage liver disease score and the follow-up period can cause the shift of circulating lymphocyte subsets in liver transplant recipients","volume":"8","author":"Pan","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2001.29167","article-title":"Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity","volume":"7","author":"Reuben","year":"2001","journal-title":"Liver Transpl"},{"key":"B22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jhep.2010.01.040","article-title":"Metabolic syndrome and liver transplantation: a review\u00a0and guide to management","volume":"53","author":"Watt","year":"2010","journal-title":"J Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001693","article-title":"mTOR inhibition and cardiovascular diseases: dyslipidemia and atherosclerosis","volume":"102","author":"Kurdi","year":"2018","journal-title":"Transplantation"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-021-01498-9","article-title":"Granzyme B-producing B cells function as a feedback loop for T helper cells in liver transplant recipients with acute rejection","volume":"44","author":"Xu","year":"2021","journal-title":"Inflammation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12967-021-02855-w","article-title":"A combination of the percentages of IFN-gamma(+)CD4(+)T cells and granzyme B(+)CD19(+)B cells is associated with acute hepatic rejection: a case control study","volume":"19","author":"Zhu","year":"2021","journal-title":"J Transl Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jgh.12700","article-title":"Hepatitis B virus infection and metabolic syndrome: fact or fiction","volume":"30","author":"Wang","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.02.003","article-title":"Association between alcohol intake, overweight, and serum lipid levels and the risk analysis associated with the development of dyslipidemia","volume":"8","author":"Shen","year":"2014","journal-title":"J Clin Lipidol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2017.03.004","article-title":"Metabolic manifestations of hepatitis C virus: diabetes mellitus, dyslipidemia","volume":"21","author":"Serfaty","year":"2017","journal-title":"Clin Liver Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.30247","article-title":"Endoplasmic reticulum stress in nonalcoholic (metabolic associated) fatty liver disease (NAFLD\/MAFLD)","volume":"123","author":"Flessa","year":"2022","journal-title":"J Cell Biochem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.2800","article-title":"Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma","volume":"157","author":"Tabrizian","year":"2022","journal-title":"JAMA Surg"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.012","article-title":"Personalized treatment of patients with very early hepatocellular carcinoma","volume":"66","author":"Vitale","year":"2017","journal-title":"J Hepatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3211-3","article-title":"Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis","volume":"21","author":"Arnaoutakis","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920701)70:1<45::AID-CNCR2820700108>3.0.CO;2-7","article-title":"Tumor encapsulation in hepatocellular carcinoma. A pathologic study of 189 cases","volume":"70","author":"Ng","year":"1992","journal-title":"Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072235","article-title":"Scoring selection criteria including total tumour volume and pretransplant percentage of lymphocytes to predict recurrence of hepatocellular carcinoma after liver transplantation","volume":"8","author":"Li","year":"2013","journal-title":"PloS One"},{"key":"B35","article-title":"Decreased granzyme B(+)CD19(+)B cells are associated with tumor progression following liver transplantation","volume":"11","author":"Li","year":"2021","journal-title":"Am J Cancer Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1306091\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T04:12:32Z","timestamp":1713154352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2024.1306091\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":35,"alternative-id":["10.3389\/fendo.2024.1306091"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2024.1306091","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"article-number":"1306091"}}